Hematology-OncologyAllogeneic Hematopoietic Cell TransplantationBệnh Graft-versus-Host
ATG versus Alemtuzumab for GvHD Prophylaxis in AML Allo-HCT: Insights from the EBMT Registry
By MedXY|Sep 17, 2026
In AML patients undergoing unrelated donor allo-HCT with intermediate-intensity conditioning, ATG-based GvHD prophylaxis demonstrated better overall and leukemia-free survival and reduced relapse compared to alemtuzumab, despite higher acut